OP White Papers - random

31. Late‑Stage Progress In Excipients For Precision Nanomedicine 5/6/2026

    View late‑stage development and GMP manufacturing of novel excipients for nanomedicines, emphasizing regulatory rigor, process optimization, analytics, and scale‑up for lipid‑based delivery systems.

32. Is Sustainability The Key To Agile Biopharma Manufacturing? 3/18/2025

    In biologics manufacturing, change is constant. Discover how new innovations and a focus on sustainability have gotten 62% of executives to prioritize eco-friendly practices, which reflects a commitment to long-term viability.

33. Enabling Digital Twins With Computational Fluid Dynamics Modeling 1/16/2025

    Embrace the transformative power of predictive modeling and digital twin technology to optimize bioprocess efficiency, ensure product quality, and drive innovation in biopharmaceutical manufacturing.

34. Flexibility In Drug Development: From Tactical Response To Strategic Discipline 8/10/2026

    Historically managed through late-stage adjustments, operational adaptability has become a strategic imperative to prevent programs from stalling under real-world pressures.

35. Overview Of Hot Melt Extrusion And Its Pharmaceutical Applications 8/31/2026

    More than 40% of NCEs face aqueous solubility challenges. Here, we examine how hot melt extrusion addresses solubility, modified release, abuse deterrence, and scale-up across pharmaceutical development.

36. Competing Through Complexity: Models To Manage Mature Products 7/6/2026

    As patented drug revenues drop from 23% to just 10% by 2034, biopharma leaders need a clear framework for matching mature product strategy to their organization's operating model and risk appetite.

37. Redefining The Analytical Frameworks Surrounding Capsid Characterization 3/5/2026

    Modern AAV manufacturing demands precise capsid characterization to distinguish empty, partial, and full particles, as regulators now require rigorous purity and potency control for clinical safety.

38. The Role Of A Consulting Firm In The IND Process 6/10/2025

    Navigate the complex IND process with expert guidance and discover how early FDA engagement can accelerate your path to clinical trials.

39. Nucleic Acid-LNP Ultrafiltration And Diafiltration 5/5/2026

    Downstream filtration can make or break LNPs at scale. See how membrane format, loading, and shear affect recovery and stability — and how alternative TFF lowers scale‑up risk.

40. Streamlining Early Drug Development: Efficient Synthesis Of Highly Potent Compounds 5/6/2026

    Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.